Novo Nordisk A/S (NYSE:NVO) stock is surging on Wednesday after the company raised its fiscal 2026 guidance, driven by increased expectations for GLP-1 product sales.

The weight loss drug maker reported first quarter sales of $15.17 billion (96.82 billion Danish kroner), beating the consensus of $11.13 billion.

Sales jumped 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the U.S.

The company reported adjusted earnings of $1.04 (6.63 Danish kroner), beating the consensus of 87 cents.

First quarter adjusted operating profit decreased by 6% at CER to 32.86 billion Danish kroner, while reported operating profit increased by 65% at CER to 59.62 billion Danish kroner, driven by a provision reversal related to the 340B Drug Pricing Program in the U.S.

Read Also:

Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug ...